RxY

RxY (part of the P/S/L Group) is a Global Healthcare Research business focused on understanding the real reasons behind treatment selection. Founded in 2018, RxY is dedicated to helping our clients understand which therapies are considered for a patient, what drives the actual treatment decision, and why therapies were not considered. Focusing on in-play patients, i.e., newly-initiating or switching, RxY provides unique insights and recommendations to drive clients patient share. RxY utilizes AI and chatbot technology to deliver precise understanding of in the moment decision making by physicians. Via our analytics teams, RxY provides deep analysis supporting: senior executives, competitor...

Atopic dermatitis,psoriasis,psoriatic arthritis,crohn's disease,ulcerative colitis,multiple sclerosis,type 2 diabetes,copd,united states,france,germany,italy,spain,united kingdom,austria,belgium,netherlands,switzerland,japan,canada,china,canada,rheumatoid arthritis,migraine,multiple myeloma,chronic lymphocytic leukemia,asthma,and atopic dermatitis

Rxy operates in the Market research industry.

Rxy's revenue is 11m - 100m

Rxy has 11 - 50 employees.